PHIA Koninklijke Philips N.V.

Philips becomes first medical device manufacturer granted new Underwriters Laboratories product cybersecurity testing firm registration

Philips becomes first medical device manufacturer granted new Underwriters Laboratories product cybersecurity testing firm registration

March 12, 2020

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company was named the first medical device manufacturer to receive a new (UL) product cybersecurity testing certification. Underwriters Laboratories (UL) is an independent global safety certification and testing company with locations worldwide.

The UL IEC 62304 certification was designed by Underwriters Laboratories to provide an overall framework to evaluate the robustness and maturity of a medical device manufacturer’s cybersecurity controls and capabilities for product development.

In support of the successful Philips firm registration for the security option of IEC 62304, UL performed a comprehensive audit of the Philips Security Center of Excellence. The Center was launched in 2015 to develop cyber-resilient products and services through security-by-design, risk assessment, vulnerability and penetration assessment, specialized trainings, and incident response.

The audit reviewed and verified core Philips product security processes, including security risk management and risk control measures, software security verification planning, change management and continuous improvement, and the Center’s laboratory quality management system.

The UL certification combines cybersecurity testing elements of the established UL 2900-2-1 standard for Software Cybersecurity for Network-Connectable Products, which focuses on the demanding requirements of healthcare and wellness systems, as well as security principles from international standards (ISO 13485 and ISO 14971).

“To receive this certification from Underwriters Laboratories, a long-established global leader in standards creation and safety testing, is a strong validation of our program and an opportunity to advance healthcare and personal health product security even further,” said Michael McNeil, Global Product Security & Services Officer, Philips.

“We’ve spent years building a successful and effective end-to-end Security by Design program, embedding security principles and best practices throughout a product’s life cycle,” McNeil added. “At Philips, we understand that our customers have high and growing expectations for the security of the solutions that they rely on. In addition, global regulatory authorities have also increased the scope and scale of product cybersecurity compliance requirements to help protect patients and consumers. We look forward to continuing to meet these critical commitments.”

For further information, please contact:

Mario Fante

Philips Global Press Office

Tel: =9226

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at . 

Attachments

EN
12/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch